Evaluation of the Ki-67 Proliferation Index and Urocortin Expression in Women with Ovarian Endometriomas

YALCİN, Serenat Eris; aydogmus, huseyin; KELEKÇİ, Sefa; DEMİR ÇALTEKİN, MELİKE; SELİM, Halime Şen; Öcal, İrfan; Yalcin, Yakup

Evaluation of the Ki-67 Proliferation Index and Urocortin Expression in Women with Ovarian Endometriomas

Serenat Eris YALCİN, (Department of Perinatology, Süleyman Demirel University School of Medicine, Isparta, Turkey)

İrfan ÖCAL, (Department of Pathology, İzmir Katip Çelebi Univesity School of Medicine, Atatürk Training and Research Hospital, İzmir, Turkey)

Yakup YALÇIN, (Department of Gynecologic Oncology, Süleyman Demirel University School of Medicine, Isparta, Turkey)

Halime Şen SELİM, (Department of Gynecology and Obstetrics, Seferihisar Hospital, İzmir, Turkey)

MELİKE DEMİR ÇALTEKİN, (Department of Gynecology and Obstetrics, Malatya Hospital, Malatya, Turkey)

Hüseyin AYDOĞMUŞ, (Department of Gynecology and Obstetrics, İzmir Katip Çelebi University School of Medicine, Atatürk Training and Research Hospital, İzmir Turkey)

Sefa KELEKÇİ (Girilmedi)

Eurasian Journal of Medicine

1 0

Yıl: 2017 Cilt: 49 Sayı: 2 Sayfa Aralığı: 107 - 112 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Evaluation of the Ki-67 Proliferation Index and Urocortin Expression in Women with Ovarian Endometriomas

Öz:

Amaç: Endometriozisin bazı hastalarda neden daha agresif ve invaziv olduğunun nedenleri bilinmemektedir. Klinik olarak belirlenen risk faktörleri populasyon bazında rekürrens prediksiyonunda değerli olmasına rağmen kişi bazında prediksiyonda hastadan elde edilen biyokimyasal markerlar daha değerlidir. Bu nedenle, rekürrens açısından anlamlı potansiyel biyomarkerların keşfi endomeriozis patogenezine ışık tutabileceği gibi rekürrens takibinde klinisyenlere yardımcı bir parametre olarak kullanılabilir.Gereç ve Yöntem: Çalışmamıza over kisti nedeniyle cerrahi geçiren ve patolojik inceleme sonucunda endometrioma tanısı konmuş 50 hasta dahil edildi. Olguların yaş, endometriozis evresi, endometrioma çapı ve lokalizasyonu, cerrahi tipi, preoperatif ve postoperatif CA 125 düzeyleri kaydedildi. Olguların arşiv patoloji preparatları Ki 67 ve anti-urocortin antikor ile boyandı. Patolojik parametreler nüks olan olgular ile olmayanlarda kıyaslanarak bu parametrelerin rekürrens ile ilişkisi araştırıldı.Bulgular: Nüks olan olguların Ki67 İndeks medyanı (7,5±6,5) nüks olmayan olguların Ki67 İndeks medyan değerinden (1±4) daha büyük olup, istatistiksel olarak anlamlıydı (p=0,003). Olguların nüks olma durumu ile ürocortin epitel boyanma yoğunluğu ve yüzdesine göre dağılımı ise istatistiksel olarak anlamlı değildi. Nüks olmayan olguların postoperatif CA 125 medyan değeri (10±17,6) nüks olan olguların CA 125 medyan değerinden (29,9±18,1) daha küçük olup bu istatistiksel olarak anlamlıydı (p=0,003).Sonuç: Ki67 proliferasyon indeksi prognoz ve rekürrens riskini predikte etmede yardımcı bir belirteç olabilir

Anahtar Kelime:

Konular: Genel ve Dahili Tıp

Ovarian Endometriomalı Kadınlarda Ki-67 Proliferasyon İndeksi ve Urokortinin Değerlendirilmesi

Öz:

Objective: The reasons why endometriosis is more aggressive and invasive in some patients are unknown. Despite the importance of population-based clinically defined risk factors in the prediction of recurrence, biochemical markers obtained from the patient are more valuable for prediction on an individual basis. Therefore, the discovery of significant potential biomarkers could be useful to clinicians for shedding light on the pathogenesis of endometriosis and in the monitoring recurrence.Materials and Methods: This study included 50 patients who underwent surgery for ovarian cysts that were diagnosed as endometrioma. The age of the patients, stage of the endometriosis, diameter and localization of endometriomas, type of surgery, and pre- and postoperative cancer antigen 125 (CA125) levels were compared between patients with and without recurrence. The archived pathology slides were stained with Ki-67 and anti-urocortin antibodies for reevaluation. By comparing the pathology parameters of the patients with and without recurrence, the association between these parameters and recurrence was investigated. Results: The median Ki-67 proliferation index of the patients with recurrence (7.5±6.5) was statistically significant compared with that of the patients without recurrence (1±4) (p=0.003). The urocortin epithelial staining intensity and percentage were not found to be statistically significant in comparison. A statistically significant difference was determined between postoperative CA125 median levels of patients without recurrence (10±17.6) and those of patients with recurrence (29.9±18.1) (p=0.003).Conclusion: The Ki-67 proliferation index may be useful for predicting prognosis and recurrence risk

Anahtar Kelime:

Konular: Genel ve Dahili Tıp

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Bhanoori M, Arvind Babu K, Pavankumar Reddy NG, et al. The vascular endothelial growth factor (VEGF) +405G>C 5’-untranslated region polymorphism and increased risk of endometriosis in South Indian women: a case control study. Hum Reprod 2005; 20: 1844-9.
2. Kim SH, Choi YM, Choung SH, Jun JK, Kim JG, Moon SY. Vascular endothelial growth factor gene +405 C/G polymorphism is associated with susceptibility to advanced stage endometriosis. Hum Reprod 2005; 20: 2904-8.
3. Huisman MA, De Heer E, Grote JJ. Cholesteatoma epithelium is characterized by increased expression of Ki-67, p53 and p21, with minimal apoptosis. Acta Otolaryngol 2003; 123: 377-82.
4. Dahmoun M, Boman K, Cajander S, Westin P, Backström T. Apoptosis, proliferation, and sex hormone receptors in superficial parts of human endometrium at the end of the secretory phase. J Clin Endocrinol Metab 1999; 84: 1737-43.
5. Park JS, Lee JH, Kim M, Chang HJ, Hwang KJ, Chang KH. Endometrium from women with endometriosis shows increased proliferation activity. Fertil Steril 2009; 92: 1246-9.
6. Vaughan J, Donaldson C, Bittencourt J, et al. Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature 1995: 378; 287-92.
7. Reyes TM, Lewis K, Perrin MH, et al. Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc Natl Acad Sci U S A 2001; 27: 2843-8.
8. Lewis K, Li C, Perrin MH, et al. Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc Natl Acad Sci U S A 2001; 19: 7570-5.
9. Agnello D, Bertini R, Sacco S, Meazza C, Villa P, Ghezzi P. Corticosteroid-independent inhibition of tumor necrosis factor production by the neuropeptide urocortin. Am J Physiol 1998; 275: E757-62.
10. Florio P, Arcuri F, Ciarmela P, et al. Identification of urocortin mRNA and peptide in the human endometrium. J Endocrinol 2002; 173: R9-14.
11. Torricelli M, De Falco G, Florio P, et al. Secretory endometrium highly expresses urocortin messenger RNA and peptide: possible role in the decidualization process. Hum Reprod 2007; 22: 92-6.
12. Hao Z, Huang Y, Cleman J, et al. Urocortin2 inhibits tumor growth via effects on vascularization and cell proliferation. Proc Natl Acad Sci U S A 2008; 105: 3939-44.
13. Toki T, Kubota J, Lu X, Nakayama K. Immunohistochemical analysis of CA125, CA19-9, and Ki-67 in stage III or IV endometriosis: positive correlation between serum CA125 level and endometriotic epithelial cell proliferation. Acta Obstet Gynecol Scand 2000; 79: 771-6.
14. Nagamani M, Kelver ME, Smith ER. CA 125 levels in monitoring therapy for endometriosis and in prediction of recurrence. Int J Fertil 1992; 37: 227-31.
15. Fedele L, Arcaini L, Vercellini P, Bianchi S, Candiani GB. Serum CA 125 measurements in the diagnosis of endometriosis recurrence. Obstet Gynecol 1988; 72: 19-22.
16. Kahyaoglu I, Kahyaoglu S, Moraloglu O, Zergeroglu S, Sut N, Batioglu S. Comparison of Ki-67 proliferative index between eutopic and ectopic endometrium: a case control study. Taiwan J Obstet Gynecol 2012; 51: 393-6.
17. Scotti S, Regidor PA, Schindler AE, Winterhager E. Reduced proliferation and cell adhesion in endometriosis. Mol Hum Reprod 2000; 6: 610-7.
18. Florio P, Torres PB, Torricelli M, Toti P, Vale W, Petraglia F. Human endometrium expresses urocortin II and III messenger RNA and peptides. Fertil Steril 2006; 86: 1766-70.
19. Novembri R, Borges LE, Carrarelli P, et al. Impaired CRH and urocortin expression and function in eutopic endometrium of women with endometriosis. J Clin Endocrinol Metab 2011; 96: 1145-50.
20. Florio P, Reis FM, Torres PB, et al. Plasma urocortin levels in the diagnosis of ovarian endometriosis. Obstet Gynecol 2007; 110: 594-600.
21. Tokmak A, Ugur M, Tonguc E, Var T, Moraloğlu O, Ozaksit G. The value of urocortin and Ca-125 in the diagnosis of endometrioma. Arch Gynecol Obstet 2011; 283: 1075-9.

APA	YALCİN S, Öcal İ, Yalcin Y, SELİM H, DEMİR ÇALTEKİN M, aydogmus h, KELEKÇİ S (2017). Evaluation of the Ki-67 Proliferation Index and Urocortin Expression in Women with Ovarian Endometriomas. , 107 - 112.
Chicago	YALCİN Serenat Eris,Öcal İrfan,Yalcin Yakup,SELİM Halime Şen,DEMİR ÇALTEKİN MELİKE,aydogmus huseyin,KELEKÇİ Sefa Evaluation of the Ki-67 Proliferation Index and Urocortin Expression in Women with Ovarian Endometriomas. (2017): 107 - 112.
MLA	YALCİN Serenat Eris,Öcal İrfan,Yalcin Yakup,SELİM Halime Şen,DEMİR ÇALTEKİN MELİKE,aydogmus huseyin,KELEKÇİ Sefa Evaluation of the Ki-67 Proliferation Index and Urocortin Expression in Women with Ovarian Endometriomas. , 2017, ss.107 - 112.
AMA	YALCİN S,Öcal İ,Yalcin Y,SELİM H,DEMİR ÇALTEKİN M,aydogmus h,KELEKÇİ S Evaluation of the Ki-67 Proliferation Index and Urocortin Expression in Women with Ovarian Endometriomas. . 2017; 107 - 112.
Vancouver	YALCİN S,Öcal İ,Yalcin Y,SELİM H,DEMİR ÇALTEKİN M,aydogmus h,KELEKÇİ S Evaluation of the Ki-67 Proliferation Index and Urocortin Expression in Women with Ovarian Endometriomas. . 2017; 107 - 112.
IEEE	YALCİN S,Öcal İ,Yalcin Y,SELİM H,DEMİR ÇALTEKİN M,aydogmus h,KELEKÇİ S "Evaluation of the Ki-67 Proliferation Index and Urocortin Expression in Women with Ovarian Endometriomas." , ss.107 - 112, 2017.
ISNAD	YALCİN, Serenat Eris vd. "Evaluation of the Ki-67 Proliferation Index and Urocortin Expression in Women with Ovarian Endometriomas". (2017), 107-112.

APA	YALCİN S, Öcal İ, Yalcin Y, SELİM H, DEMİR ÇALTEKİN M, aydogmus h, KELEKÇİ S (2017). Evaluation of the Ki-67 Proliferation Index and Urocortin Expression in Women with Ovarian Endometriomas. Eurasian Journal of Medicine, 49(2), 107 - 112.
Chicago	YALCİN Serenat Eris,Öcal İrfan,Yalcin Yakup,SELİM Halime Şen,DEMİR ÇALTEKİN MELİKE,aydogmus huseyin,KELEKÇİ Sefa Evaluation of the Ki-67 Proliferation Index and Urocortin Expression in Women with Ovarian Endometriomas. Eurasian Journal of Medicine 49, no.2 (2017): 107 - 112.
MLA	YALCİN Serenat Eris,Öcal İrfan,Yalcin Yakup,SELİM Halime Şen,DEMİR ÇALTEKİN MELİKE,aydogmus huseyin,KELEKÇİ Sefa Evaluation of the Ki-67 Proliferation Index and Urocortin Expression in Women with Ovarian Endometriomas. Eurasian Journal of Medicine, vol.49, no.2, 2017, ss.107 - 112.
AMA	YALCİN S,Öcal İ,Yalcin Y,SELİM H,DEMİR ÇALTEKİN M,aydogmus h,KELEKÇİ S Evaluation of the Ki-67 Proliferation Index and Urocortin Expression in Women with Ovarian Endometriomas. Eurasian Journal of Medicine. 2017; 49(2): 107 - 112.
Vancouver	YALCİN S,Öcal İ,Yalcin Y,SELİM H,DEMİR ÇALTEKİN M,aydogmus h,KELEKÇİ S Evaluation of the Ki-67 Proliferation Index and Urocortin Expression in Women with Ovarian Endometriomas. Eurasian Journal of Medicine. 2017; 49(2): 107 - 112.
IEEE	YALCİN S,Öcal İ,Yalcin Y,SELİM H,DEMİR ÇALTEKİN M,aydogmus h,KELEKÇİ S "Evaluation of the Ki-67 Proliferation Index and Urocortin Expression in Women with Ovarian Endometriomas." Eurasian Journal of Medicine, 49, ss.107 - 112, 2017.
ISNAD	YALCİN, Serenat Eris vd. "Evaluation of the Ki-67 Proliferation Index and Urocortin Expression in Women with Ovarian Endometriomas". Eurasian Journal of Medicine 49/2 (2017), 107-112.